Show/Hide Menu
Hide/Show Apps
anonymousUser
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Açık Bilim Politikası
Açık Bilim Politikası
Frequently Asked Questions
Frequently Asked Questions
Browse
Browse
By Issue Date
By Issue Date
Authors
Authors
Titles
Titles
Subjects
Subjects
Communities & Collections
Communities & Collections
Functional Application Of İmmununoliposomes Encapsulating Celecoxib On Colon Cancer Cell Lines.
Date
2010-12-31
Author
Banerjee, Sreeparna
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
0
views
0
downloads
Long term regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been correlated with reduced risk of variety of cancers. Celecoxib is a new generation NSAID that can selectively inhibit activity of cyclooxygenase-2 (COX-2) Celecoxib serves as a chemopreventive agent in colorectal cancer. Therefore there is growing interest in developing drug delivery systems for celecoxib, Targeting will be carried out by conjugation of a chimeric monoclonal antibody (Cetuximab) against the Epidermal Growth Factor Receptor (EGFR). EGFR, which binds to epidermal growth factor, is essential in the normal maintenance of cellular growth and function. However, the receptor is known to be dysregulated in 25-77% of colorectal cancers and 85% of metastatic colorectal cancers. In this project we propose to prepare PEGylated liposomes encapsulating celecoxib, which will be converted immunoliposomes by conjugating to an anti-EGFR antibody. The combined inhibition of COX-2 by celecoxib and EGFR by cetuximab has been previously shown to synergistically reduce the metastatic potential of breast cancer in in vivo models (Gupta et al., 2007). Preliminary studies carried out in our laboratory indicate successful liposomal encapsulation and release of celecoxib (Deniz, Sade, Severcan, Keskin, Tezcaner & Banerjee, 2009). We therefore propose that the immunoliposomal preparation for the targeted delivery of celecoxib may hold promise for future therapeutic opportunities in colon cancer.
URI
https://hdl.handle.net/11511/59835
Collections
Graduate School of Natural and Applied Sciences, Project and Design